secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2022-03-28T23:59:59+00:00
Accession:  0001193125-22-085927
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics reports Q4 2021 net loss $22.0M; cash $485.3M; TNG908 Fast Track
--------------------------------------------------------------------------------

- Net loss Q4 2021: $22.0M ($0.25/share) vs $8.9M ($0.22/share) in Q4 2020; full year $58.2M ($0.94/share).
- Revenue Q4 2021: $5.7M vs $9.1M in Q4 2020; full year $37.0M vs $7.7M in 2020 (Gilead amendment effect).
- Cash, equivalents & marketable securities: $485.3M as of Dec 31, 2021, expected to fund operations into H2 2024.
- TNG908 (PRMT5 inhibitor) granted FDA Fast Track; Phase 1/2 trial expected to start Q2 2022.
- Target 3 and USP1 development candidates expected Q2 and H2 2022, respectively; leadership team expanded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312522085927/0001193125-22-085927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312522085927/d240035d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-085927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer